A citation-based method for searching scientific literature

Marcelo Maia Pinheiro, Caroline Lais Stoppa, Claudete Justina Valduga, Cristina Eunice Okuyama, Renata Gorjão, Regina Mara Silva Pereira, Susana Nogueira Diniz. Eur J Pharm Sci 2017
Times Cited: 39







List of co-cited articles
314 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Dipeptidyl peptidase 4 inhibitor sitagliptin maintains β-cell function in patients with recent-onset latent autoimmune diabetes in adults: one year prospective study.
Yunjuan Zhao, Lin Yang, Yufei Xiang, Lingjiao Liu, Gan Huang, Zhaofeng Long, Xia Li, R David Leslie, Xiangbing Wang, Zhiguang Zhou. J Clin Endocrinol Metab 2014
73
28

Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor.
Lei Tian, Jie Gao, Jianqiang Hao, Yu Zhang, Huimin Yi, Timothy D O'Brien, Robert Sorenson, Jian Luo, Zhiguang Guo. Endocrinology 2010
84
25

Sitagliptin exerts an antinflammatory action.
Antoine Makdissi, Husam Ghanim, Mehul Vora, Kelly Green, Sanaa Abuaysheh, Ajay Chaudhuri, Sandeep Dhindsa, Paresh Dandona. J Clin Endocrinol Metab 2012
171
25

Possible Long-Term Efficacy of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, for Slowly Progressive Type 1 Diabetes (SPIDDM) in the Stage of Non-Insulin-Dependency: An Open-Label Randomized Controlled Pilot Trial (SPAN-S).
Takuya Awata, Akira Shimada, Taro Maruyama, Yoichi Oikawa, Nobuyuki Yasukawa, Susumu Kurihara, Yumi Miyashita, Masako Hatano, Yuichi Ikegami, Masafumi Matsuda,[...]. Diabetes Ther 2017
24
37

Human Th17 cells express high levels of enzymatically active dipeptidylpeptidase IV (CD26).
Bertram Bengsch, Bianca Seigel, Tobias Flecken, Julia Wolanski, Hubert E Blum, Robert Thimme. J Immunol 2012
101
20

Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system.
C Klemann, L Wagner, M Stephan, S von Hörsten. Clin Exp Immunol 2016
164
20

Sitagliptin, a DPP-4 inhibitor, alters the subsets of circulating CD4+ T cells in patients with type 2 diabetes.
Yoshimasa Aso, Maiko Fukushima, Masaaki Sagara, Teruo Jojima, Toshie Iijima, Kunihiro Suzuki, Atsushi Momobayashi, Kikuo Kasai, Toshihiko Inukai. Diabetes Res Clin Pract 2015
23
34

Combined treatment with sitagliptin and vitamin D in a patient with latent autoimmune diabetes in adults.
E Rapti, S Karras, M Grammatiki, A Mousiolis, X Tsekmekidou, E Potolidis, P Zebekakis, M Daniilidis, K Kotsa. Endocrinol Diabetes Metab Case Rep 2016
21
33

C-peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2-year double-blind, randomized, controlled study.
Odd Erik Johansen, Bernhard O Boehm, Valdemar Grill, Peter A Torjesen, Sudipta Bhattacharya, Sanjay Patel, Kristiane Wetzel, Hans-Juergen Woerle. Diabetes Care 2014
42
17

Saxagliptin improves glycaemic control and C-peptide secretion in latent autoimmune diabetes in adults (LADA).
R Buzzetti, P Pozzilli, R Frederich, N Iqbal, B Hirshberg. Diabetes Metab Res Rev 2016
32
21

CD26-mediated co-stimulation in human CD8(+) T cells provokes effector function via pro-inflammatory cytokine production.
Ryo Hatano, Kei Ohnuma, Junpei Yamamoto, Nam H Dang, Chikao Morimoto. Immunology 2013
47
17

Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?
Roger Yazbeck, Gordon S Howarth, Catherine A Abbott. Trends Pharmacol Sci 2009
179
15

The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves β-cell mass in non-obese diabetic mice.
Jacob Jelsing, Niels Vrang, Søren B van Witteloostuijn, Michael Mark, Thomas Klein. J Endocrinol 2012
36
16

Four-year clinical remission of type 1 diabetes mellitus in two patients treated with sitagliptin and vitamin D3.
Marcelo Maia Pinheiro, Felipe Moura Maia Pinheiro, Margareth Afonso Torres. Endocrinol Diabetes Metab Case Rep 2016
14
42


A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients.
Noriko Satoh-Asahara, Yousuke Sasaki, Hiromichi Wada, Mayu Tochiya, Azusa Iguchi, Reiko Nakagawachi, Shinji Odori, Shigeo Kono, Koji Hasegawa, Akira Shimatsu. Metabolism 2013
124
15

Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study.
K V S Hari Kumar, Altamash Shaikh, Pitambar Prusty. Diabetes Res Clin Pract 2013
61
15

Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice.
A D Dobrian, Q Ma, J W Lindsay, K A Leone, K Ma, J Coben, E V Galkina, J L Nadler. Am J Physiol Endocrinol Metab 2011
105
15

Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial.
S L Ellis, E G Moser, J K Snell-Bergeon, A S Rodionova, R M Hazenfield, S K Garg. Diabet Med 2011
89
15

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Benjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, P Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Robert Frederich, Stephen D Wiviott, Elaine B Hoffman,[...]. N Engl J Med 2013
15


Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study.
Seoyoung C Kim, Sebastian Schneeweiss, Robert J Glynn, Michael Doherty, Allison B Goldfine, Daniel H Solomon. Ann Rheum Dis 2015
56
15

Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC.
V Stalin Raj, Huihui Mou, Saskia L Smits, Dick H W Dekkers, Marcel A Müller, Ronald Dijkman, Doreen Muth, Jeroen A A Demmers, Ali Zaki, Ron A M Fouchier,[...]. Nature 2013
15

The new insights from DPP-4 inhibitors: their potential immune modulatory function in autoimmune diabetes.
Yunjuan Zhao, Lin Yang, Xiangbing Wang, Zhiguang Zhou. Diabetes Metab Res Rev 2014
39
12

Type 1 Diabetes Prevention in NOD Mice by Targeting DPPIV/CD26 Is Associated with Changes in CD8⁺T Effector Memory Subset.
Núria Alonso, María Teresa Julián, Jorge Carrascal, Roger Colobran, Irma Pujol-Autonell, Silvia Rodriguez-Fernández, Aina Teniente, Marco Antonio Fernández, Antoni Miñarro, María Carmen Ruiz de Villa,[...]. PLoS One 2015
7
71

One year remission of type 1 diabetes mellitus in a patient treated with sitagliptin.
Marcos M Lima-Martínez, Ernesto Guerra-Alcalá, Miguel Contreras, José Nastasi, Janelle A Noble, Constantin Polychronakos. Endocrinol Diabetes Metab Case Rep 2014
12
41

Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial.
Satish K Garg, Emily G Moser, Bruce W Bode, Leslie J Klaff, William R Hiatt, Christie Beatson, Janet K Snell-Bergeon. Endocr Pract 2013
66
12

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
Jennifer B Green, M Angelyn Bethel, Paul W Armstrong, John B Buse, Samuel S Engel, Jyotsna Garg, Robert Josse, Keith D Kaufman, Joerg Koglin, Scott Korn,[...]. N Engl J Med 2015
12


Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
William B White, Christopher P Cannon, Simon R Heller, Steven E Nissen, Richard M Bergenstal, George L Bakris, Alfonso T Perez, Penny R Fleck, Cyrus R Mehta, Stuart Kupfer,[...]. N Engl J Med 2013
12


DPP4 in Diabetes.
Diana Röhrborn, Nina Wronkowitz, Juergen Eckel. Front Immunol 2015
171
12

Caveolin-1 triggers T-cell activation via CD26 in association with CARMA1.
Kei Ohnuma, Masahiko Uchiyama, Tadanori Yamochi, Kunika Nishibashi, Osamu Hosono, Nozomu Takahashi, Shinichiro Kina, Hirotoshi Tanaka, Xin Lin, Nam H Dang,[...]. J Biol Chem 2007
81
12

Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV.
Anne-Marie Lambeir, Christine Durinx, Simon Scharpé, Ingrid De Meester. Crit Rev Clin Lab Sci 2003
611
12

Sitagliptin in glutamic acid decarboxylase antibody-positive diabetes mellitus.
Narayanan Kandasamy, Graham Lennox, Anand K Annamalai, Gerald Maguire, Amanda I Adler. Endocr Pract 2012
9
44



CD26: a negative selection marker for human Treg cells.
Francisco J Salgado, Amparo Pérez-Díaz, Nora M Villanueva, Olaya Lamas, Pilar Arias, Montserrat Nogueira. Cytometry A 2012
31
12

Combining MK626, a novel DPP-4 inhibitor, and low-dose monoclonal CD3 antibody for stable remission of new-onset diabetes in mice.
Lei Ding, Conny A Gysemans, Geert Stangé, Yves Heremans, Yixing Yuchi, Tatiana Takiishi, Hannelie Korf, Marie Chintinne, Richard D Carr, Harry Heimberg,[...]. PLoS One 2014
15
26

Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.
J Andrew Pospisilik, Jennifer Martin, Timothy Doty, Jan A Ehses, Nathalie Pamir, Francis C Lynn, Shalea Piteau, Hans-Ulrich Demuth, Christopher H S McIntosh, Raymond A Pederson. Diabetes 2003
271
10

The effect of anti-CD26 antibodies on DNA synthesis and cytokine production (IL-2, IL-10 and IFN-gamma) depends on enzymatic activity of DP IV/CD26.
D Reinhold, T Kähne, M Täger, U Lendeckel, F Bühling, U Bank, S Wrenger, J Faust, K Neubert, S Ansorge. Adv Exp Med Biol 1997
17
23

Decreased regulatory function of CD4+CD25+CD45RA+ T cells and impaired IL-2 signalling pathway in patients with type 2 diabetes mellitus.
Vida Sheikh, Alireza Zamani, Elham Mahabadi-Ashtiyani, Hanieh Tarokhian, Shiva Borzouei, Mahdi Alahgholi-Hajibehzad. Scand J Immunol 2018
14
28

The alteration of Th1/Th2/Th17/Treg paradigm in patients with type 2 diabetes mellitus: Relationship with diabetic nephropathy.
Cuiping Zhang, Chunchun Xiao, Peng Wang, Wenhua Xu, Aimei Zhang, Qing Li, Xiucai Xu. Hum Immunol 2014
68
10

Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function.
Kei Ohnuma, Nam H Dang, Chikao Morimoto. Trends Immunol 2008
162
10

Targeting dipeptidyl peptidase IV (CD26) suppresses autoimmune encephalomyelitis and up-regulates TGF-beta 1 secretion in vivo.
A Steinbrecher, D Reinhold, L Quigley, A Gado, N Tresser, L Izikson, I Born, J Faust, K Neubert, R Martin,[...]. J Immunol 2001
124
10

Is there an association between dipeptidyl peptidase-4 inhibitors and autoimmune disease? A population-based study.
Khalaf Kridin, Kyle Amber, Mogher Khamaisi, Doron Comaneshter, Erez Batat, Arnon D Cohen. Immunol Res 2018
20
20

Deficiency of CD26 results in a change of cytokine and immunoglobulin secretion after stimulation by pokeweed mitogen.
Shuling Yan, Didier Marguet, Jörg Dobers, Werner Reutter, Hua Fan. Eur J Immunol 2003
85
10

Functional role of CD26 on human B lymphocytes.
F Bühling, U Junker, D Reinhold, K Neubert, L Jäger, S Ansorge. Immunol Lett 1995
87
10

Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy.
Rosa Barreira da Silva, Melissa E Laird, Nader Yatim, Laurence Fiette, Molly A Ingersoll, Matthew L Albert. Nat Immunol 2015
147
10

CD26, adenosine deaminase, and adenosine receptors mediate costimulatory signals in the immunological synapse.
R Pacheco, J M Martinez-Navio, M Lejeune, N Climent, H Oliva, J M Gatell, T Gallart, J Mallol, C Lluis, R Franco. Proc Natl Acad Sci U S A 2005
167
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.